Pharma major Lupin has said the US health regulator has issued three observations after inspection of its Tarapur facility in Maharashtra.
The inspection of Tarapur facility was carried out by the United States Food and Drug administration (USFDA) between September 16-20, 2019.
“The inspection at the Tarapur facility closed with three observations,” the firm said in a regulatory filing.
Lupin did not elaborate on the nature of the observations.
“The Company is confident of addressing them satisfactorily,” the filing added.